SCHEMBL1209657

SCHEMBL1209657

O=C1OC2(c3ccccc3Oc3ccccc32)c2ccc(Cl)c(Cl)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 6/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 2/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
SMAD3 P84022 2/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
PRMT1 Q99873 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 2/20 0.39
ALOX12 P18054 2/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
BRCA1 P38398 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9244110 0.84 AHR (0.44) FTOMAPTHPGDMEN1HTT
SCHEMBL11112647 0.84 FTO (0.43) FTOMAPTHPGDMEN1HTT
SCHEMBL273427 0.83 FTO (0.59) FTOMAPTHPGDMEN1HTT
SCHEMBL9474742 0.82 FTO (0.58) FTOMAPTHPGDMEN1HTT
SCHEMBL10606910 0.80 FTO (0.40) FTOMAPTHPGDMEN1HTT
SCHEMBL3641991 0.79 HPGD (0.39) FTOMAPTHPGDMEN1HTT
SCHEMBL1608754 0.78 SMAD3 (0.46) FTOMAPTHPGDMEN1HTT
SCHEMBL546598 0.77 FTO (0.48) FTOMAPTHPGDMEN1HTT
SCHEMBL19549151 0.76 MEN1 (0.42) FTOMAPTHPGDMEN1HTT
SCHEMBL284851 0.76 MAPT (0.65) FTOMAPTHPGDMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023136334-A1 METHOD FOR PRODUCING COMPOUND REPRESENTED BY FORMULA (I) 富士フイルム株式会社 2023-07-20 WO disclosed
US-9505255-B2 Thermal imaging members and methods ZINK HOLDINGS LLC 2016-11-29 US disclosed
US-20150119237-A1 THERMAL IMAGING MEMBERS AND METHODS ZINK IMAGING, INC. (US) 2015-04-30 US disclosed
EP-2485900-B1 MULTICOLOUR THERMAL IMAGING MATERIAL ZINK IMAGING INC (US) 2014-05-21 EP disclosed
US-8722574-B2 Thermal imaging members and methods ZINK IMAGING, INC. (US) 2014-05-13 US disclosed
US-20130059726-A1 THERMAL IMAGING MEMBERS AND METHODS ZINK IMAGING, INC. 2013-03-07 US disclosed
US-8372782-B2 Imaging system ZINK IMAGING, INC. (US) 2013-02-12 US disclosed
EP-2485900-A1 MULTICOLOUR THERMAL IMAGING MATERIAL Zink Imaging, Inc. (US) 2012-08-15 EP disclosed
EP-1597084-B1 IMAGING SYSTEM ZINK IMAGING LLC (US) 2012-04-11 EP disclosed
US-20110105754-A1 NOVEL RHODAMINE DYES ZINK IMAGING, INC. 2011-05-05 US disclosed
EP-1493781-A1 Rhodamine dye derivatives and their use for phase change inks Xerox Corporation (US) 2005-01-05 EP disclosed
US-20040261657-A1 PHASE CHANGE INKS CONTAINING COLORANT COMPOUNDS XEROX CORPORATION 2004-12-30 US disclosed
US-6835238-B1 Hot melts XEROX CORPORATION 2004-12-28 US disclosed
US-20040191668-A1 Novel dyes and use thereof in imaging members and methods ZINK HOLDINGS LLC 2004-09-30 US disclosed
WO-2004078875-A2 NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS POLAROID CORPORATION (US) 2004-09-16 WO disclosed
WO-2004078479-A2 IMAGING SYSTEM POLAROID CORPORATION (US) 2004-09-16 WO disclosed
US-20040176248-A1 Imaging system ZINK HOLDINGS LLC 2004-09-09 US disclosed
EP-0226264-B1 LIGHT-INDUCED KILLING OF CARCINOMA CELLS THE GENERAL HOSPITAL CORPORATION (US) 1990-10-31 EP disclosed
EP-0226264-A1 Light-induced killing of carcinoma cells THE GENERAL HOSPITAL CORPORATION (US) 1987-06-24 EP disclosed
US-4651739-A CHROMOGENS, LIPOPHILIC, LIPIDS THE GENERAL HOSPITAL CORPORATION (US) 1987-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059726-A1 THERMAL IMAGING MEMBERS AND METHODS HEATR1, HEATR6, HSPBP1 FTO 2371/4885MAPT 94/4885HPGD 3416/4885
US-20150119237-A1 THERMAL IMAGING MEMBERS AND METHODS HEATR1, HEATR6, HSPBP1 FTO 2371/4885MAPT 94/4885HPGD 3416/4885
US-20110105754-A1 NOVEL RHODAMINE DYES IK, RB1, ABCG2 FTO 1992/4885MAPT 503/4885HPGD 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.